AcelRx Pharmaceuticals Q2 EPS $(0.40) Beats $(0.53) Estimate, Sales $253.00K Beat $70.00K Estimate
Portfolio Pulse from vinayak@benzinga.com
AcelRx Pharmaceuticals reported Q2 earnings per share of $(0.40), beating the analyst consensus estimate of $(0.53) by 24.53%. This is a 66.67% increase over losses from the same period last year. The company also reported quarterly sales of $253.00K, beating the analyst consensus estimate of $70.00K by 261.43%, but this is a 55.61% decrease over sales from the same period last year.
August 10, 2023 | 8:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AcelRx Pharmaceuticals reported better than expected Q2 earnings per share and sales, but sales decreased compared to the same period last year.
AcelRx Pharmaceuticals reported better than expected Q2 earnings per share and sales, which is generally positive for the stock. However, the decrease in sales compared to the same period last year could be a concern for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100